Fast Five Quiz: Molecular and Biomarker Analysis in Non–Small Cell Lung Cancer (NSCLC)

Daniel S. Schwartz, MD


January 28, 2022

The MAP/ERK pathway experiences unregulated signaling in patients with NSCLC who have activating BRAF mutations. A specific BRAF mutation that results in a change in amino acid position 600 (p.V600E) is associated with responsiveness to combined BRAF/MEK inhibition.

Other signaling pathways involved in NSCLC include the RAS/MAPK, MEK/ERK, and PI3K/AKT pathways.

Learn more about genetic mutations in NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.